The FDA 513(g) submission is a significant step in the regulatory process for medical devices. If approved, this could potentially lead to increased revenues for Coeptis Therapeutics, as it would allow the company to market and sell the CD38 in vitro companion diagnostic. This could have a positive impact on the company's stock price in the short term.